Armin Koch

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Respiratory Syndrome Coronavirus

Top Venues

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Anika Großhennig, Nele Henrike Thomas, Werner Brannath, Armin Koch
How to avoid concerns with the interpretation of two primary endpoints if significant superiority in one is sufficient for formal proof of efficacy. Pharmaceutical statistics (2023)
Sebastian Häckl, Armin Koch, Florian Lasch
Type-I-error rate inflation in mixed models for repeated measures caused by ambiguous or incomplete model specifications. Pharmaceutical statistics (2023)
Florian Lasch, Lorenzo Guizzaro, Lukas Aguirre Dávila, Kirsten Müller-Vahl, Armin Koch
Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study. Pharmaceutical statistics 20 (3) (2021)
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron, Armin Koch, Martin Posch, Justine Rochon, Anja Schiel
The use of external controls: To what extent can it currently be recommended? Pharmaceutical statistics 20 (6) (2021)
Robert Hemmings, Armin Koch
Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke. Pharmaceutical statistics 18 (2) (2019)
Sebastian Häckl, Armin Koch, Florian Lasch
Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols. Pharmaceutical statistics 18 (6) (2019)